Sanofi Pasteur, the vaccines division of Sanofi, reports that results of an efficacy study is a step closer to making dengue the next vaccine-preventable disease.
Sanofi Pasteur, the vaccines division of Sanofi, reports that results of an efficacy study is a step closer to making dengue the next vaccine-preventable disease.
Sanofi points to The Lancet’s published results showing the overall efficacy of the drug maker’s vaccine against symptomatic dengue in 56.5% in children aged 2 to 14 years old after a three-dose vaccination schedule. Results also show an 88·5% reduction of dengue haemorrhagic fever, the severe form of dengue. To date, 27,000 children, adolescents and adults have been vaccinated with three doses of the candidate dengue vaccine throughout the clinical studies.
Dengue is a threat to nearly half the world’s population; it is a particularly pressing health priority in many countries in Asia and Latin America. Each year, an estimated 500,000 people with severe dengue require hospitalization. According to the Sanofi study, one in twenty children in the control group suffered from dengue each year.
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.